- Home
- STSS vs GNPX Comparison
STSS vs GNPX Comparison
Compare STSS & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STSS
- GNPX
- Stock Information
- Founded
- STSS 2017
- GNPX 2009
- Country
- STSS United States
- GNPX United States
- Employees
- STSS N/A
- GNPX N/A
- Industry
- STSS Medical/Dental Instruments
- GNPX Biotechnology: Pharmaceutical Preparations
- Sector
- STSS Health Care
- GNPX Health Care
- Exchange
- STSS Nasdaq
- GNPX Nasdaq
- Market Cap
- STSS 5.1M
- GNPX 5.5M
- IPO Year
- STSS 2022
- GNPX 2018
- Fundamental
- Price
- STSS $9.47
- GNPX $0.30
- Analyst Decision
- STSS
- GNPX
- Analyst Count
- STSS 0
- GNPX 0
- Target Price
- STSS N/A
- GNPX N/A
- AVG Volume (30 Days)
- STSS 3.4M
- GNPX 23.7M
- Earning Date
- STSS 08-13-2025
- GNPX 08-14-2025
- Dividend Yield
- STSS N/A
- GNPX N/A
- EPS Growth
- STSS N/A
- GNPX N/A
- EPS
- STSS N/A
- GNPX N/A
- Revenue
- STSS $222,722.00
- GNPX N/A
- Revenue This Year
- STSS N/A
- GNPX N/A
- Revenue Next Year
- STSS N/A
- GNPX N/A
- P/E Ratio
- STSS N/A
- GNPX N/A
- Revenue Growth
- STSS N/A
- GNPX N/A
- 52 Week Low
- STSS $3.36
- GNPX $0.14
- 52 Week High
- STSS $1,840.74
- GNPX $3.97
- Technical
- Relative Strength Index (RSI)
- STSS 51.87
- GNPX 68.43
- Support Level
- STSS $8.75
- GNPX $0.20
- Resistance Level
- STSS $10.93
- GNPX $0.40
- Average True Range (ATR)
- STSS 2.53
- GNPX 0.04
- MACD
- STSS -0.35
- GNPX 0.02
- Stochastic Oscillator
- STSS 8.74
- GNPX 58.13
About STSS Sharps Technology Inc.
Sharps Technology Inc is a medical device company. It offers syringes and other safety products. Sharps provensa, Securgard, and Sologard are ultra-low waste smart safety syringes designed to eliminate potentially infectious and accidental needlestick injuries.
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.